Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.